文献速递脊柱关节炎

轴性脊柱关节炎中转换肿瘤坏死因子抑制剂的研究综述

Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis.
PubMed 文献 · Semin Arthritis Rheum · 2017-04-25

该综述通过PubMed检索评估了轴性脊柱关节炎(axSpA)患者转换TNF-α抑制剂的疗效与药物留存情况。共纳入21项报告转换TNF抑制剂数据的研究,发现转换对相当比例初始或第二种TNF抑制剂治疗失败的患者有益且不良事件未增加,但第二、三种TNF抑制剂的药物留存率通常低于第一种。

要点

  • 转换TNF抑制剂对初始或第二种TNF抑制剂治疗失败的axSpA患者有益,且不良事件未增加。
  • 第二、三种TNF抑制剂的2年药物留存率通常低于第一种TNF抑制剂。
  • 转换TNF抑制剂患者的常见特征包括女性、年龄较大、病情更重、症状负担更高、ESR升高、完全强直和附着点炎。

核心结论

  • 当第一种甚至第二种TNF抑制剂治疗失败时,换用另一种TNF抑制剂并非不合理的临床治疗决策。

研究设计与样本

  • 通过PubMed文献检索,检索词组合包括强直性脊柱炎、脊柱关节病、脊柱关节炎、转换、药物留存和TNF/肿瘤坏死因子,以识别报告axSpA患者转换生物治疗结局数据的已发表文章。
  • 共筛选134项研究,其中21项被确定报告了携带axSpA或强直性脊柱炎诊断的患者转换TNF抑制剂的数据。

主要发现

  • 从第一种TNF抑制剂转换最常见的原因依次为缺乏疗效(14-68%)、疗效丧失(13-61%)和不良事件/耐受性差(13-57%)。
  • 转换TNF抑制剂对相当比例对初始甚至第二种TNF抑制剂治疗无应答的axSpA患者有益,且不良反应未增加。
  • 第二种TNF抑制剂的药物留存率(2年时47-72%)或第三种TNF抑制剂(2年时49%)通常低于第一种TNF抑制剂(2年时58-75%)。
  • 初治TNF患者应答的预测因素包括HLA-B27阳性、无附着点炎、年龄≤40岁、C反应蛋白水平升高、功能状态良好和病程较短。
  • 药物留存的预测因素包括男性和外周关节炎。

临床怎么用

  • 对于第一种或第二种TNF抑制剂治疗失败的axSpA患者,可考虑换用另一种TNF抑制剂。
  • 转换TNF抑制剂时需关注女性、年龄较大、病情更重、症状负担更高、ESR升高、完全强直和附着点炎等常见特征。
  • 初治TNF患者中,HLA-B27阳性、无附着点炎、年龄≤40岁、CRP升高、功能状态良好和病程较短提示应答可能性较高。
  • 男性和外周关节炎与较好的药物留存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of switching tumor necrosis factor (TNF)-alpha inhibitors on patients with axial spondyloarthritis (axSpA). METHODS: PubMed literature searches were conducted using combinations of search terms including ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, switch/switching, drug survival, and TNF/tumor necrosis factor to identify published articles with data on outcomes related to switching biologic therapies in patients with axSpA. RESULTS: Of the 134 studies screened, 21 were identified as reporting data on switching TNF inhibitors in patients carrying a diagnosis of axSpA or ankylosing spondylitis. The most common reasons for switching from the first TNF inhibitor were lack of efficacy (14-68%), loss of efficacy (13-61%), and adverse events/poor tolerability (13-57%). Switching TNF inhibitors was beneficial for a substantial proportion of patients with axSpA who failed to respond to initial or even second TNF inhibitor therapy and adverse effects were not enhanced. Drug survival rates were generally lower for the second (47-72% at 2 years) or third TNF inhibitor (49% at 2 years) than for the first TNF inhibitor (58-75% at 2 years). Predictors of responses in TNF-naïve patients included HLA-B27 positivity, absence of enthesitis, age ≤40 years, elevated C-reactive protein level, good functional status, and shorter disease duration. Predictors of drug survival included male sex and peripheral arthritis. Common characteristics of patients who switched TNF inhibitors included female sex, older age, more severe disease, greater symptom burden, higher erythrocyte sedimentation rate, complete ankyloses, and enthesitis. CONCLUSION: When the first or even the second TNF inhibitor fails, switching to an alternate one is not an unreasonable clinical therapeutic decision.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017. PMID: 28551170. doi:10.1016/j.semarthrit.2017.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。